CN¥71.20
7.65%
Hong Kong, Nov 04, 03:00 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
CNE100003F01
Symbol
6185

CanSino Biologics Stock price

CN¥71.20
-31.44 30.63% 1M
+9.69 15.75% 6M
+8.35 13.29% YTD
-5.53 7.21% 1Y
-12.40 14.83% 3Y
-204.73 74.20% 5Y
-321.91 81.89% 10Y
-321.91 81.89% 20Y
Hong Kong, Closing price Wed, Nov 04 2026
+5.06 7.65%
ISIN
CNE100003F01
Symbol
6185
Industry

AI Insights on CanSino Biologics Insights AI Insights on CanSino Biologics

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Is CanSino Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.

Key metrics

Basic
Market capitalization
CN¥11.2b
Enterprise Value
CN¥10.3b
Net debt
positive
Cash
CN¥1.8b
Shares outstanding
230.3m
Valuation
P/E
413.4
P/S | estimate
9.0 | 7.7
EV/Sales | estimate
8.4 | 7.1
EV/FCF | ex SBC
negative | -
P/B
2.2
Dividends
DPS
CN¥0.00
Yield 1Y | 5Y
0.0% | 0.1%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
CN¥1.2b | CN¥1.5b
EBITDA
-
EBIT
CN¥31.4m
Net Income
CN¥40.6m
Free Cash Flow | ex SBC
CN¥-194.1m | -
Growth
Revenue | estimate
33.5% | 36.7%
EBITDA
-
EBIT
116.2%
Net Income
124.3%
Free Cash Flow
28.3%
Margin
Gross
74.4%
EBITDA
-
EBIT
2.5%
Net
3.3%
Free Cash Flow | ex SBC
-15.7% | -
Financial Health
Equity Ratio
69.0%
Return on Equity
0.6%
ROCE
0.5%
ROIC
0.6%
Debt/Equity
0.2
More
EPS
CN¥0.2
FCF per Share
CN¥-0.8
Short interest
-
Employees
1k
Rev per Employee
CN¥940.0k

CanSino Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CanSino Biologics forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a CanSino Biologics forecast:

Buy
86%
Hold
14%

Financial data from CanSino Biologics

Jun '26
+/-
%
1,235 1,235
34% 34%
100%
- Direct Costs 316 316
66% 66%
26%
919 919
25% 25%
74%
- Selling and Administrative Expenses 631 631
6% 6%
51%
- Research and Development Expense 321 321
15% 15%
26%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 31 31
116% 116%
3%
Net Profit 41 41
124% 124%
3%

In millions CNY.

Don't miss a Thing! We will send you all news about CanSino Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,134 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.

Head office China
CEO Mr. Yu
Employees 1,134
Website www.cansinotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today